eye prize initi buy pt
proprietari consum work point toward opportun
doc survey point toward opportun
panoptix use conserv assumpt see driver push top-
line growth toward initi lrp base case model call
top-lin adj ep growth support pt bull case see ep
surpass lrp window support upsid target
proprietari work survey favor alcon at-iol panoptix
find forecast growth cataract procedur next year
mix shift at-iol exit exit translat
share gain monofoc next year outlook share alcon
acrysof at-iol strong interest panoptix surgeon express
interest adopt upon fda clearanc late
proprietari work consum len survey posit
find half respond will switch weeklies/monthli
daili nearli half will switch express interest
impli gain across len wearer repres signific potenti tailwind
daili broadli find daili also support
upsid coopervis target buy next
upsid potenti base survey work panoptix
conserv base upsid case panoptix appli increment share
translat potenti revenu upsid contact len survey
support higher mix daili share gain upon launch
base case scenario translat upsid potenti
uplift base vision result
financi top-lin low-dd ep conserv assumpt
made minor tweak pre-spin assumpt includ higher growth
implant panoptix better reflect survey find higher growth
vision also support survey work end adj om
lrp preliminari better reflect mix vision manufactur
benefit increas exit lrp fine-tun intang
assumpt initi outlook call top-lin report growth
adj ebitda margin adj ep
launch buy pt upsid bull case scenario
base case pt deriv use forward pe forward ebitda
multipl blend forecast captur benefit product cycl
vision manufactur effort discount year use
wacc upsid target appli assum top-lin reach adj ebita margin
reach adj ep surpass lrp window
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
buy thesi predic potenti signific ep
acceler initi lrp
work differenti base proprietari survey work
inclus cataract surgeon explor demand
panoptix consum len explor
demand
driver ep acceler outlook better industri
ophthalmolog versu med-tech
revenu upsid sihi daili len margin
expans vision manufactur modern
non-oper benefit lower tax lower interest cost
color initi outlook ep call april
potenti contribut bp time
compound-annual-growth-rate surgic driven launch panoptix
implant vitreoretin equip
compound-annual-growth-rate contact lens support
gm expans vision manufactur
larg scale initi lrp
acceler debt servic share buyback near-term
compound-annual-growth-rate surgic driven launch panoptix
assum share gain at-iol
compound-annual-growth-rate contact lens support
assum share gain
gm expans
vision
one larg scale transact initi lrp
excess capit post alloc share buyback
compound-annual-growth-rate surgic limit uptak panoptix due
cost/reimburs barrier
compound-annual-growth-rate contact lens limit uptak
share loss daili
delay vision manufactur beyond limit
larg scale initi lrp prove dilut
acceler debt servic share buyback near-term
pleas see import disclosur inform page report
financi summari market data
estim valuat
estim exclud one-tim item
pleas see import disclosur inform page report
tabl content
pm summari find consum survey
 pm summari potenti signific ep ramp exit
lrp confluenc driver panoptix vision
 alc valuat snapshot base case assumpt
bull
 compani snapshot undisput leader ophthalmolog
 ophthalmolog faster grow attract vs
closer look surgic leader implant consum
surgeri
 closer look vision leader contact lens ocular
 recap lrp growth driver at-iol panoptix sihi
 proprietari work consum survey focus alc
ophthalmolog survey screen methodolog final
volum
current iol util trend at-iol expect gain
share next
 surgeon prefer bullish current leader alcon
 qualit feedback acrysof prefer astigmat tecni
presbyopia
 reimburs still repres barrier at-iol
panoptix bullish outlook outcom physician uptak
pleas see import disclosur inform page report
 consum len survey deep dive contact
len wearer trend effort explor growth
 modal trend data suggest share gain
 share trend brand alc under-index daili prefer
 price discount daili would
trigger shift across wearer captur survey
base case upsid scenario uplift
 bull case upsid scenario uplift
aa top-lin outlook conserv gate w/sever upsid
ab margin outlook base case call margin
ac ep outlook base case point inflect bull
case see ep
ae flow sight annual support
outer year
af alc valuat snapshot base case assumpt
bull case
ag appendix board manag overview
ah appendix ii glossari term use report ocular disord
appendix vii qualit comment ophthalmolog
survey at-iol
appendix viii qualit commentari around differ iol
pleas see import disclosur inform page report
pm summari find consum survey chart
datapoint at-iol mix exit expect surgeon express interest adopt panoptix
upon fda clearanc consum respond look switch weeklies/monthli daili nearli half
express interest alcon current under-index daili solid posit monthli airoptix
exhibit adopt trifoc panoptix fda approv
exhibit expect contact mix modal
exhibit would consid switch
exhibit discount switch
pleas see import disclosur inform page report
pm summari potenti signific ep ramp exit lrp confluenc
initi lrp call msd top-lin growth bodi languag suggest low-to-mid adj om
current base msd capital-expenditure spend high-teen tax rate ophthalmolog consum survey find
support compani least achiev like exceed msd top-lin target lrp period consid
revenu upsid target upsid target panoptix conserv assumpt beyond
revenu gain big swing factor new contact len manufactur platform forecast improv output
reduc cost per len capital-expenditure fulli implement next year back-of-envelop math
appli coopervis pre post sauflon gm profil high pre high post alcon forward contact len outlook use modest
assumpt use methodolog see cog benefit time
exhibit ebita ebitda project margin
balanc sheet outook factor debt rais ahead spin form bridg loan price
price base recent file base initi revenu margin outlook annual project
call compani exceed preliminari approach preliminari
translat increas end lrp versu manag target preliminari increas key
differ preliminari initi model around level annual intang amort expect next sever
year confirm compani annual amort associ intang transfer novn
spin annual burden expect decreas exit assum large-scal
exhibit debt leverag outlook
pleas see import disclosur inform page report
alc valuat snapshot base case assumpt bull case
run blend valuat approach come base bull case target alc share combin discount forward
comp dcf discount forward sotp take-out scenario use discount forward approach order captur
true ep power compani consid mix benefit new product launch panoptix other
manufactur benefit across vision base case pt deriv use forward pe forward ebitda multipl
blend forecast discount use wacc upsid target appli assum top-
line reach adj ebita margin reach adj ep surpass lrp window
exhibit alc bull case valu base lrp profil
pleas see import disclosur inform page report
clinic trial clearanc risk panoptix current
fda experi eu w/ panoptix strong contact
len risk minim futur project mig like carri
risk
color initi outlook april confirm
novn releas certain financi disclosur upcom
call april follow detail outlook alc
like toward end may
product recal risk cypass mig voluntari recal
result share swing
share shift alcon under-index daili vision lost
ground past due capit constraint product
price although price stabl ophthalmolog versu
area med-tech ortho cardio select area portfolio
 surgic consum could suscept
reimburs although reimburs stabl
ophthalmolog versu area med-tech ortho cardio
select area portfolio at-iol cataract surgeri face payer
potenti amazon entri len space enter directli
acquisit relev preced entri pharmaci
channel result lost market cap
dplo
advers tax rule alc subsidiari apl may requir pay
claw-back amount fribourg tax author
apl fail remain tax resid fribourg continu
certain busi activ fribourg employ certain
minimum number employe fribourg
chang swiss privileg canton regim earlier year jan
feder act tax reform ahv financ traf
propos reduc corpor tax rate
current level sign law lower swiss tax rate
potenti result ep side near-term
intern execut stock like under-perform compani fall
short lrp target
chang swiss privileg canton regim may earlier
year januari swiss author file suffici number
signatur request referendum feder act
tax reform ahv financ traf propos revis
canton tax law inclus reduc corpor tax rate
current level public vote take place
re-bal june alc share potenti elig
inclus russel indic later year may
size inclus determin may style
inclus determin june preliminari add/delet list
expect june reconstitut date
regulatori clearanc launch panoptix current
fda review expect complet follow
late launch phase roll-out
spheric like come earli follow toric multifoc
time-frame
meet includ american academi ophthalmolog
take place oct american societi cataract
refract surgeri ascr take place may
british contact len associ bcla take place may
look cadenc meet ascr could
ideal venu launch unveil panoptix
announc pre-announc guidanc issuanc
guidanc revis catalyst alc share volatil
purchas price also trigger alc share shift
pleas see import disclosur inform page report
plan prepar separ play close year culmin novn sharehold meet
took place feb basel switzerland recent compani obtain approv list swiss exchang
new york stock exchang nyse receiv notic effect sec registr effect
march specif spin-transact novarti distribut pro rata basi dividend-in-kind tax-neutr basi
swiss withhold us feder incom tax rule alcon alc share everi novarti share alcon alc
everi novarti adr held close april regular-way trade alc commenc april
exhibit timelin major event alcon
compani snapshot undisput leader ophthalmolog
alcon lead stand-alon player across global ophthalmolog space view one attract endmarket
across global med-tech sector vision focus develop correct lens ocular health portfolio dri
eye well len care solut within surgic compani compet implant hold posit
consum hold posit surgic equip also hold posit vision compani
compet contact lens hold global posit ocular health hold global posit
exhibit snapshot alcon market posit
pleas see import disclosur inform page report
ophthalmolog faster grow attract vs med-tech market
alcon size global ophthalm market compet per year grow annual mani respect
view conserv cut categori weight averag market growth rate wamgr view competitor
high-growth profil sever product nich consid within surgic compani peg underli growth consumbl
equip lsd see implant grow msd inclus select product potenti
grow sustain next sever year at-iol panoptix within surgic compani peg underli growth
consumbl equip lsd see implant grow msd inclus select product
potenti grow sustain next sever year at-iol panoptix alcon see vision grow
annual inclus ocular health also vision conserv versu buy view
market recent hsd growth perform
use higher blend averag vision closer see wamgr global ophthalm market closer
compar well broader med-tech categori asid favor growth profil ophthalmolog also
sever favor end-market dynam includ less exposur manag care vision ocular health lower
patient acquisit cost vision ocular health patient demand inelast cataract retina glaucoma surgeri
necessarili elect high degre custom sticki consum vision ophthalm surgeon surgeri
exhibit major medic devic market growth
pleas see import disclosur inform page report
closer look surgic leader implant consum surgeri
alcon surgic sbu develop implant surgic equip relat consum address virtual everi major ocular
condit includ cataract retina disord refract disord glaucoma implant side alcon lead offer
acrysof famili intra-occular lens iol includ rang product monofoc iol basic cataract surgeri
moder price end advanced-technolog iol refract vision disord correct concurr cataract
surgeri premium end recent ancillari launch within implant ultrasert clareon autonom pre-load iol
deliveri system key product launch eu await fda clearanc panopt trifoc at-iol fda clearanc expect
late earli surgic equip side alcon largest collect fleet cataract vitreoretin excimer/
femtosecond lasik surgic platform lead surgic system centurion phacoemulsif cataract remov
constel vitreoretin surgeri wavelight refract laser use lasik although compani disclos
surgic instal base estim system base surgic equip revenu run-rat
estim averag across platform refractive/vitreoretin phaco
use life consum within surgic sbu essenti serv razor surgic system blade includ array
micro-incision instrument miv probe infus system softwar solut among item
alcon mark global surgic nearli exit inclus implant grow compound-annual-growth-rate
implant grow compound-annual-growth-rate surgic equipment/oth grow compound-annual-growth-rate exit alcon held
roughli global market sale inclus share implant share consum
equipment/oth
pleas see import disclosur inform page report
closer look vision leader contact lens ocular health
alcon vision sbu develop consum health product refract disord includ one deepest portfolio
daili dispos reusabl color-enhanc correct lens ocular health portfolio dri eye well len care
solut within contact lens compani current posit premium provid given first-to-market statu key
new technolog space includ rang silicon hydrogel materi becom standard across multipl
modal water gradient offer exist brand vision includ daili dispos offer optix
monthli replac offer list price premium rang versu competitor sourc contact
walgreen brand ocular includ systan suit artifici tear dri eye condit opti-free/clear
line contact len solut
alcon mark global vision nearli exit inclus contact lens grow compound-annual-growth-rate
versu outlook ocular health solut grow compound-annual-growth-rate exit alcon held roughli
global market sale inclus share contact lens share ocular health
pleas see import disclosur inform page report
recap lrp growth driver at-iol panoptix sihi daili
alcon manag host two capit market event new york london late provid initi lrp year
call msd top-lin growth bodi languag suggest low-to-mid adj om current
base msd capital-expenditure spend high-teen tax rate although co point toward sever driver aim bring cost
overtim biggest swing factor overal revenu growth combin product mix overal volum granularli
compani indic nearli nt-growth come new launch exist vertic includ implant surgeri
contact lens ocular health among driver co see biggest growth potenti new launch within at-iol
extens
proprietari work consum survey focus alc growth driver
focus proprietari survey work compani two largest near-term growth driver implant within surgic
contact lens within vision implant within surgic conduct survey among ophthalm surgeon perform
high volum annual cataract surgeri order gaug demand trend among current avail iol offer well
alcon pend launch panoptix trifoc iol space expect late earli contact lens within vision
conduct survey current contact len user order gaug demand trend across modal length wear
brand gaug futur demand alcon silicon hydrogel sihi daili launch expect
exhibit summari doctor survey
exhibit summari consum survey
pleas see import disclosur inform page report
ophthalmolog survey screen methodolog final respond
search target ophthalmologist use varieti practic characterist screen criteria includ annual cataract
procedur volum experi use mix iol product categori monofoc toric accomod multifoc experi
use mix lead iol brand alcon acrysof tecni envista among final sampl surgeon group
perform averag nearli cataract surgeri nearli experi monofoc toric iol
also experi implant multifoc iol half experi implant advanc
accommod iol brand level acrysof alcon tecni univers recogn suit product
show high level crystalen given strong level familiar across sever len type brand well
high surgic volum believ sampl strong potenti indic adopt trend
exhibit mix iol solut use practic
practic dynam refract mix bullish outlook volum
ask final group respond provid color around practic dynam term refract patient mix techniqu
employ perform cataract surgeri outlook procedur volum next sever year patient mix
well balanc presbyopia preval refract disord treat cataract surgeri follow myopia
astigmat balanc blend ideal consid differ condit target specif iol design
surgic techniqu respond perform tradit phacoemulsif versu laser-assist surgeri despit
high mix tradit phaco versu laser-assist procedur at-iol util high sampl volum outlook
bullish doc forecast growth cataract procedur next average volum expect surpass
exhibit averag mix refract case treat
pleas see import disclosur inform page report
current iol util trend at-iol expect gain share next
sampl physician report averag case mix monofoc iol versu at-iol bullish versu alcon
current target penetr rang data confirmatori at-iol prefer patient
need multi-dist solut correct astigmat suffer pre-exist condit lastli ask respond
comment expect util trend go forward data also posit categori sampl surgeon
forecast case mix shift at-iol exit exit translat share gain monofoc
exhibit iol prefer among surgeon survey
exhibit iol procedur trend next
surgeon prefer bullish current leader alcon
ask respond comment brand prefer across current lead product at-iol space alcon acrysof suit
tecni suit envista trulign crystalen offer data among sampl point toward clear prefer
alcon offer respond indic use acrysof product case follow
tecni at-iol across brand look ahead data margin less bullish alcon respond point
toward annual share slippag away acrysof next product still maintain comfort
lead share data suggest tecni pois take share acrysof brand
view total collect datapoint cataract surgeri volum growth next at-iol share set expand
next rel modest share slippag tecni per year next point toward growth
alcon acrysof at-iol among surgeon respond
exhibit at-iol share brand
pleas see import disclosur inform page report
qualit feedback acrysof prefer astigmat tecni presbyopia
overal share heavili concentr alcon acrysof tecni brand peel onion back explor
surgeon prefer two offer depend type case treat first explor prefer
astigmat case found posit bia toward acrysof qualit comment posit versu neutral-to-
neg among posit less rotat better visual acuiti multipl distanc better post-op outcom
cite convers among neutral-to-neg post-op halo glare pco format cite
exhibit qualit respond commentari regard alcon acrysof perform astigmat patient
pleas see import disclosur inform page report
qualit feedback tecni at-iol astigmat case less bullish rel feedback acrysof
comment posit versu neutral neg among posit good mid-dist clariti extend field depth
edof less post-op care cite convers post-op rotat limit near-dist acuiti glare/halo
cite disadvantag among neutral view tecni good select case intermedi acuiti cite
exhibit qualit respond commentari regard tecni perform astigmat patient
pleas see import disclosur inform page report
qualit feedback alcon acrysof at-iol presbyopia case less posit versu feedback receiv astigmat
comment posit astigmat versu neutral-to-neg astigmat among
posit good near-dist acuiti consist outcom cite favor featur convers among
neg post-op glisten light slitter post-op complaint cite neutral comment either point
okay outcom indic earli trial phase product
exhibit qualit respond commentari regard alcon acrysof perform presbyopia patient
pleas see import disclosur inform page report
qualit feedback tecni at-iol presbyopia case strikingli favor versu feedback receiv
astigmat comment posit astigmat versu neutral-to-neg astigmat among
posit long histori consistent/good result favor feedback multi-dist acuiti least post-op symptom
cite advantag convers among neg post-op glare limit near-dist acuiti cite
common disadvantag neutral comment indic respond also trial phase product
exhibit qualit respond commentari regard tecni perform presbyopia patient
pleas see import disclosur inform page report
reimburs still repres barrier at-iol adopt
despit gener feedback at-iol posit term volum adopt prefer complex case want
explor cost reimburs commonli cite key gate factor prevent wide-scal patient adopt
dynam acut us reimburs coverag at-iol limit versu monofoc iol cataract surgeri
turn increas out-of-pocket cost patient journey technolog scale survey data indic patient cost
greater at-iol implant versu monofoc iol cataract surgeri given surpris see
respond rank cost limit reimburs premium solut singl biggest barrier at-iol adopt versu factor
outcom surgeon learn curv surgic skill
exhibit estimate patient cost cataract w/iol surgeri
exhibit rank adopt barrier at-iol
exhibit select qualit feedback cost reimburs barrier at-iol adopt
pleas see import disclosur inform page report
panoptix bullish outlook outcom physician uptak despit cost
despit clear advantag versu monofoc iol particularli serv solut cataract patient co-morbid refract
condit current at-iol offer still limit solv concurr multi-dist acuiti high preval
post-operative condit halo glare len movement next technolog evolut at-iol space trifoc lens aim
correct limit bend light enter eye near intermedi far distanc focus onto singl
focal point retina world data eu promis evid indic trifoc iol reduc elimin
need glass contact lens cataract patient
consid advantag ask respond comment whether view trifoc at-iol
perceiv benefit versu current monofoc at-iol order guag demand alcon panoptix offer expect
gain fda clearanc late earli time-frame feedback overwhelmingli posit respond view
panoptix potenti benefit fewer halo better multi-dist clariti patient satisfact cite
surgeon envis adopt panoptix approv fda later year despit persist concern around patient cost
exhibit trifoc offer benefit current at-iol
exhibit adopt trifoc panoptix fda approv
exhibit select qualit feedback futur adopt plan trifoc panoptix upon fda clearanc
pleas see import disclosur inform page report
